Quick Answer
GRI Bio, Inc. reported Research And Development Expense of $6.82 million for the year ending 2025.
- GRI Bio, Inc. showed an increase of +81.0% in Research And Development Expense from 2024 to 2025.
- This data is from GRI Bio, Inc.'s annual report (Form 10-K), filed with the SEC on January 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $883.0 thousand | Q2 2020: $808.0 thousand | Q3 2020: $733.0 thousand | Q1 2021: $1.77 million | Q2 2021: $1.20 million | Q3 2021: $215.0 thousand | Q1 2022: $1.27 million | Q2 2022: $59.0 thousand | Q3 2022: $63.0 thousand | Q1 2023: $116.0 thousand | Q2 2023: $880.0 thousand | Q3 2023: $1.19 million | Q1 2024: $933.0 thousand | Q2 2024: $877.0 thousand | Q3 2024: $1.13 million | Q1 2025: $1.64 million | Q2 2025: $1.88 million | Q3 2025: $1.77 million.
- Over the full 6 years of available data (2020 to 2025), GRI Bio, Inc.'s Research And Development Expense has grown by 83.9%.
- Historical annual values: Fiscal year 2025: $6.82 million | Fiscal year 2024: $3.77 million | Fiscal year 2023: $3.23 million | Fiscal year 2022: $242.0 thousand | Fiscal year 2021: $5.19 million | Fiscal year 2020: $3.71 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: